Liposomal Bupivacaine in Total Knee Arthroplasty

• Status: Withdrawn
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Liposomal bupivacaine is a novel local anesthetic designed for prolonged pain relief. Despite its long-acting analgesic potential, liposomal bupivacaine is significantly more expensive than other local anesthetic alternatives. The primary aim of this investigation is to examine whether or not liposomal bupivacaine provides superior pain relief or clinically significant opioid-sparing effects versus a control to justify its cost.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Miller Orthopedic Specialists
• Collaborators: CHI Health Mercy Hospital; Creighton University Medical Center
• Treatments: Bupivacaine; Epinephrine; Epinephryl borate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Morphine; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Racepinephrine

Criteria

Inclusion Criteria:

• Patients undergoing a primary unilateral total knee arthroplasty by the PI of the trial

Exclusion Criteria:

• Patients with a sensitivity to marcaine

• Pregnant or lactating women

• Non-English speaking individuals